BR112022009409A2 - Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem - Google Patents
Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendemInfo
- Publication number
- BR112022009409A2 BR112022009409A2 BR112022009409A BR112022009409A BR112022009409A2 BR 112022009409 A2 BR112022009409 A2 BR 112022009409A2 BR 112022009409 A BR112022009409 A BR 112022009409A BR 112022009409 A BR112022009409 A BR 112022009409A BR 112022009409 A2 BR112022009409 A2 BR 112022009409A2
- Authority
- BR
- Brazil
- Prior art keywords
- indene
- dihydro
- pharmaceutically acceptable
- acceptable salt
- dihydrobenzofuran
- Prior art date
Links
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 title abstract 8
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 abstract 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 abstract 1
- 208000024720 Fabry Disease Diseases 0.000 abstract 1
- 208000015872 Gaucher disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000022292 Tay-Sachs disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
NOVOS DERIVADOS QUE TÊM GRUPAMENTO 2,3-DIHIDRO-1H-INDENO OU 2,3-DIHIDROBENZOFURANO OU SAL FARMACEUTICAMENTE ACEITÁVEL DOS MESMOS E COMPOSIÇÕES FARMACÊUTICAS QUE OS COMPREENDEM. A presente invenção fornece um novo composto que tem um grupamento 2,3-dihidro-1H-indeno ou 2,3-dihidrobenzofurano ou um sal farmaceuticamente aceitável do mesmo, um processo para a preparação do mesmo, uma composição farmacêutica que compreende o mesmo e um uso do mesmo. O composto que tem um grupamento 2,3-dihidro-1H-indeno ou 2,3-dihidrobenzofurano ou um sal farmaceuticamente aceitável do mesmo tem uma atividade inibidora contra a glicosilceramida sintase (GCS) e, portanto, pode ser aplicado de forma útil para prevenção ou tratamento de várias doenças associadas à GCS, tais como doença de Gaucher, doença de Fabry, doença de Tay-Sachs, doença de Parkinson etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190146679 | 2019-11-15 | ||
| PCT/KR2020/015864 WO2021096238A1 (en) | 2019-11-15 | 2020-11-12 | Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009409A2 true BR112022009409A2 (pt) | 2022-08-09 |
Family
ID=75911374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009409A BR112022009409A2 (pt) | 2019-11-15 | 2020-11-12 | Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230002379A1 (pt) |
| EP (2) | EP4041733B1 (pt) |
| JP (1) | JP2023503830A (pt) |
| KR (1) | KR20210059632A (pt) |
| CN (1) | CN114829361B (pt) |
| AU (1) | AU2020384066A1 (pt) |
| BR (1) | BR112022009409A2 (pt) |
| CA (1) | CA3154313A1 (pt) |
| ES (1) | ES2984255T3 (pt) |
| MX (1) | MX2022005679A (pt) |
| PL (1) | PL4041733T3 (pt) |
| RS (1) | RS65662B1 (pt) |
| WO (1) | WO2021096238A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| KR20200071752A (ko) | 2017-10-18 | 2020-06-19 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 이미다조-피리딘 화합물 |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
| CA3093527A1 (en) | 2018-03-13 | 2019-09-19 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| CA3226162A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| KR20240057365A (ko) * | 2022-10-24 | 2024-05-02 | 주식회사유한양행 | 다이메틸-2,3-다이하이드로-1h-인덴 유도체의 개선된 제조방법 |
| KR20240057364A (ko) * | 2022-10-24 | 2024-05-02 | 주식회사유한양행 | 다이메틸-2,3-다이하이드로-1h-인덴 유도체의 신규 염 및 이의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
| EP2594564B1 (en) | 2007-05-31 | 2016-09-28 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| WO2010014554A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| AU2012231275A1 (en) * | 2011-03-18 | 2013-10-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| WO2013059119A1 (en) * | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| MX2016003486A (es) * | 2013-09-20 | 2016-06-28 | Biomarin Pharm Inc | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. |
| WO2019079626A1 (en) * | 2017-10-19 | 2019-04-25 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
-
2020
- 2020-11-12 KR KR1020200150785A patent/KR20210059632A/ko unknown
- 2020-11-12 AU AU2020384066A patent/AU2020384066A1/en active Pending
- 2020-11-12 EP EP20887669.8A patent/EP4041733B1/en active Active
- 2020-11-12 CA CA3154313A patent/CA3154313A1/en active Pending
- 2020-11-12 RS RS20240700A patent/RS65662B1/sr unknown
- 2020-11-12 WO PCT/KR2020/015864 patent/WO2021096238A1/en active Application Filing
- 2020-11-12 PL PL20887669.8T patent/PL4041733T3/pl unknown
- 2020-11-12 CN CN202080075084.9A patent/CN114829361B/zh active Active
- 2020-11-12 BR BR112022009409A patent/BR112022009409A2/pt unknown
- 2020-11-12 US US17/755,843 patent/US20230002379A1/en active Pending
- 2020-11-12 JP JP2022527911A patent/JP2023503830A/ja active Pending
- 2020-11-12 MX MX2022005679A patent/MX2022005679A/es unknown
- 2020-11-12 EP EP24163536.6A patent/EP4389744A1/en active Pending
- 2020-11-12 ES ES20887669T patent/ES2984255T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023503830A (ja) | 2023-02-01 |
| CN114829361B (zh) | 2024-07-16 |
| WO2021096238A1 (en) | 2021-05-20 |
| CA3154313A1 (en) | 2021-05-20 |
| EP4041733A1 (en) | 2022-08-17 |
| PL4041733T3 (pl) | 2024-09-23 |
| EP4041733C0 (en) | 2024-05-08 |
| EP4041733B1 (en) | 2024-05-08 |
| CN114829361A (zh) | 2022-07-29 |
| MX2022005679A (es) | 2022-06-27 |
| AU2020384066A1 (en) | 2022-04-21 |
| ES2984255T3 (es) | 2024-10-29 |
| EP4389744A1 (en) | 2024-06-26 |
| RS65662B1 (sr) | 2024-07-31 |
| US20230002379A1 (en) | 2023-01-05 |
| EP4041733A4 (en) | 2023-08-30 |
| KR20210059632A (ko) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009409A2 (pt) | Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem | |
| BR112023015527A2 (pt) | Inibidores de cdk e métodos de uso destes | |
| BR112022002991A2 (pt) | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos | |
| CL2020002032A1 (es) | Cristal de un compuesto derivado de 7,8-difluoro-6,11-dihidrodibenzotiepina, composición farmacéutica, útil en reducir el tiempo de alivio de los síntomas de la influenza para tratar y/o prevenir una infección provocada por el virus de la influenza. (divisional solicitud 201900325). | |
| BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
| BR112021022659A2 (pt) | Compostos triarílicos para o tratamento de doenças pd-l1 | |
| BR112012027062A2 (pt) | composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica | |
| BR112018067442A2 (pt) | composto, composição farmacêutica, método de inibir a atividade da amina oxidase, método de tratar uma condição e uso de um composto | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| BRPI1011838B8 (pt) | compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk | |
| WO2019133770A3 (en) | Glycolate oxidase inhibitors for the treatment of disease | |
| BR112022019492A2 (pt) | Inibidores de rip1k | |
| BR112022002378A2 (pt) | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos | |
| MX2020011490A (es) | Derivado de 2-amino-2-(1,2,3-triazol-4-il)propan-1,3-diol de un compuesto novedoso para inhibir directamente la actividad de la asm, y uso del mismo. | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
| BR112022000782A2 (pt) | Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| MX2023012844A (es) | Un inhibidor de xantina oxidase. | |
| BR112022026908A2 (pt) | Inibidores de rip1k | |
| BR112023022524A2 (pt) | Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112022012368A2 (pt) | Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |